Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

(2021) Arsela Prelaj et al.   EUROPEAN JOURNAL OF CANCER

1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)

(2021) J. Bar et al.   ANNALS OF ONCOLOGY

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

(2021) Keunchil Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.

(2021) James Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

(2021) Caicun Zhou et al.   JAMA Oncology

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC

(2020) Julia Roeper et al.   Oncotarget

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

(2020) Valerio Gristina et al.   CANCER TREATMENT REVIEWS

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

(2020) Zofia Piotrowska et al.   JOURNAL OF CLINICAL ONCOLOGY

Landscape of lung cancer molecular biology in a NON-selected population.

(2019) Rosa Ana Marcos et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

(2019) Haixia Li et al.   LUNG CANCER

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations

(2019) Shouzheng Wang et al.   Thoracic Cancer

Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations

(2019) Jenn-Yu Wu et al.   Clinical Lung Cancer

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis

(2019) Yanxin Chen et al.   BMC CANCER

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

(2019) Gwo-Fuang Ho et al.   BMC CANCER

1529PPhase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)

(2019) T M Kim et al.   ANNALS OF ONCOLOGY

482PInterim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC

(2019) F De Marinis et al.   ANNALS OF ONCOLOGY

Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

(2019) Yung-Hsuan Chen et al.   BMC CANCER

Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer

(2019) Tejas Patil et al.   Clinical Lung Cancer

P2.14-47 Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer

(2019) C.K. Liam et al.   Journal of Thoracic Oncology

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study

(2019) Lei Lei et al.   Cancer Medicine

Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

(2019) Jang Ho Cho et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

(2019) B. van Veggel et al.   LUNG CANCER

Worldwide Frequency of Commonly Detected EGFR Mutations

(2018) Rondell P. Graham et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies

(2018) Federico Cappuzzo et al.   Future Oncology

159P Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: A Spanish retrospective multicentre study

(2018) M.T. Moran Bueno et al.   Journal of Thoracic Oncology

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations

(2018) Chih-Yen Tu et al.   Oncotarget

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

(2018) Yi-Long Wu et al.   JOURNAL OF CLINICAL ONCOLOGY

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Thanyanan Reungwetwattana et al.   JOURNAL OF CLINICAL ONCOLOGY

Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases

(2018) Matthew Evans et al.   PATHOLOGY & ONCOLOGY RESEARCH

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

(2018) Wan-Ling Tan et al.   BMC CANCER

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations

(2018) Yen-Ting Lin et al.   INTERNATIONAL JOURNAL OF CANCER

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)

(2018) Andrés F. Cardona et al.   LUNG CANCER

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

(2018) Yi-Long Wu et al.   OncoTargets and Therapy

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors

(2018) Ming-Ju Tsai et al.   Cancers

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

(2018) Youjin Kim et al.   Journal of Thoracic Oncology

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients

(2017) Natalia Sutiman et al.   Journal of Thoracic Oncology

Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib

(2017) Zong‐Han Yao et al.   ONCOLOGIST

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma

(2017) Sheng-Kai Liang et al.   Oncotarget

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

(2016) Yoshiko Urata et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China

(2016) Jianlin Xu et al.   LUNG CANCER

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

(2016) Yue-Lun Zhang et al.   Oncotarget

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

(2015) Jarushka Naidoo et al.   CANCER

Management of EGFR mutated nonsmall cell lung carcinoma patients

(2015) Bogdan Grigoriu et al.   EUROPEAN RESPIRATORY JOURNAL

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma

(2015) Zoltan Lohinai et al.   Journal of Thoracic Oncology

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

(2015) Chao-Hua Chiu et al.   Journal of Thoracic Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis

(2015) Sabrina Rossi et al.   Molecular Diagnosis & Therapy

Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2015) Amit Jain et al.   PLoS One

Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer

(2014) M. J. Peters et al.   INTERNAL MEDICINE JOURNAL

Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations

(2014) Toshihiko Iuchi et al.   International Journal of Clinical Oncology

26 Treatment and outcome in epidermal growth factor receptor mutant non-small cell lung cancer: A retrospective audit across four NHS trusts

(2014) E. Killick et al.   LUNG CANCER

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma

(2014) Jeng-Sen Tseng et al.   PLoS One

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer

(2013) Victor H.F. Lee et al.   Journal of Thoracic Oncology

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

(2013) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes

(2013) Myriam Locatelli-Sanchez et al.   LUNG

EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival

(2013) M. Faehling et al.   LUNG CANCER

Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders

(2013) Shih-Hsin Hsiao et al.   PLoS One

Advanced Lung Adenocarcinoma Harboring a Mutation of the Epidermal Growth Factor Receptor: CT Findings after Tyrosine Kinase Inhibitor Therapy

(2013) Chang-Min Choi et al.   RADIOLOGY

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

(2013) H. Yasuda et al.   Science Translational Medicine

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

(2012) Jin-Ji Yang et al.   LUNG CANCER